Current Report Filing (8-k)
January 05 2017 - 4:13PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of The
Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 3, 2017
CELGENE CORPORATION
(Exact name of registrant as specified in its
charter)
Delaware
|
001-34912
|
22-2711928
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
86 Morris Avenue, Summit, New Jersey
|
|
07901
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
|
|
|
Registrant’s telephone number, including
area code: (908) 673-9000
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 8.01 OTHER EVENTS
On January 3, 2017, Celgene Corporation announced that it will
present a business update on the Company in addition to unaudited 2016 financial results and an updated financial outlook at the
35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 10:30 a.m. EST.
Attached hereto and incorporated herein by reference as Exhibit 99.1
is the Press Release announcement.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit 99.1 – Press Release dated January
3, 2017
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CELGENE CORPORATION
|
|
|
Date: January 5, 2017
|
By:
|
/s/ Peter N. Kellogg
|
|
|
Peter N. Kellogg
Executive Vice President and
Chief Financial Officer
(principal financial and accounting
officer)
|
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
|
|
|
|
99.1
|
Press Release dated January 3, 2017
|
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about Celgene Corporation (NASDAQ): 0 recent articles
More Celgene Corp /de/ News Articles